LX-9211 is under clinical development by Lexicon Pharmaceuticals and currently in Phase II for Postherpetic Neuralgia. According to GlobalData, Phase II drugs for Postherpetic Neuralgia have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LX-9211’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LX-9211 overview

LX-9211 (BMS-986176) is under development for the treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia. The drug candidate is administered through oral route as tablets. The drug candidate targets AP2 associated kinase 1 (AAK1).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company engaged in the development of sotagliflozin in type 1 diabetes, which was the subject of a separate NDA, in which NDA is in positive results of the third phase clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for heart failure and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.

For a complete picture of LX-9211’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.